| 0.7004 -0.139 (-16.55%) | 06-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.41 |
1-year : | 1.78 |
| Resists | First : | 1.2 |
Second : | 1.52 |
| Pivot price | 1.16 |
|||
| Supports | First : | 0.69 |
Second : | 0.57 |
| MAs | MA(5) : | 0.89 |
MA(20) : | 1.18 |
| MA(100) : | 0.97 |
MA(250) : | 1.36 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 1.9 |
D(3) : | 3.4 |
| RSI | RSI(14): 30.6 |
|||
| 52-week | High : | 2.83 | Low : | 0.54 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ HUMA ] has closed above bottom band by 1.3%. Bollinger Bands are 127% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 16 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.87 - 0.87 | 0.87 - 0.88 |
| Low: | 0.68 - 0.69 | 0.69 - 0.7 |
| Close: | 0.69 - 0.7 | 0.7 - 0.71 |
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.
Mon, 22 Jun 2026
Davidson Kempner reports 4.74% stake in Humacyte (NASDAQ: HUMA) - Stock Titan
Fri, 19 Jun 2026
Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet - Yahoo Finance
Tue, 16 Jun 2026
Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Mon, 15 Jun 2026
Humacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Thu, 11 Jun 2026
Humacyte, Inc. Announces Underwritten Public Offering of Common Stock - Quiver Quantitative
Wed, 10 Jun 2026
Biotech Humacyte prices $50M sale to fund Symvess, dialysis filing - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 270 (M) |
| Held by Insiders | 1.9057e+008 (%) |
| Held by Institutions | 7.5 (%) |
| Shares Short | 44,700 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.0519e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 704 % |
| Return on Equity (ttm) | -51.5 % |
| Qtrly Rev. Growth | 2.02e+006 % |
| Gross Profit (p.s.) | -1.75 |
| Sales Per Share | -166.46 |
| EBITDA (p.s.) | -3.32195e+007 |
| Qtrly Earnings Growth | -0.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -102 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 34.45 |
| Dividend | 0 |
| Forward Dividend | 4.014e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|